CLDX (Celldex Therapeutics) FCF Margin %: -448,180.00% (As of Mar. 2026)

What is Celldex Therapeutics FCF Margin %?

Celldex Therapeutics CLDX +3.43% 57 FCF Margin % is -448,180.00% as of Mar. 2026. GuruFocus rates CLDX with a GF Score™ of 57/100 and a GF Value™ of $6.88 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 958 Biotechnology companies, Celldex Therapeutics ranks worse than 96.35% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Celldex Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-67.23 Mil. Celldex Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.02 Mil. Therefore, Celldex Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -448,180.00%.

As of today, Celldex Therapeutics's current FCF Yield % is -8.18%.

The historical rank and industry rank for Celldex Therapeutics's FCF Margin % or its related term are showing as below:

CLDX' s FCF Margin % Range Over the Past 10 Years
Min: -26125.75 Med: -1460.82 Max: -565.6
Current: -26125.75

During the past 13 years, the highest FCF Margin % of Celldex Therapeutics was -565.60%. The lowest was -26125.75%. And the median was -1460.82%.

CLDX's FCF Margin % is ranked worse than
96.35% of 958 companies
in the Biotechnology industry
Industry Median: -85.21 vs CLDX: -26125.75

Celldex Therapeutics FCF Margin % Related Terms

Celldex Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics FCF Margin % Chart

Celldex Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

-1,336.44

-4,478.57

-1,585.20

-2,274.89

-13,829.06

Celldex Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															-7,861.44	-6,127.81	0.00	-53,901.65	-448,180.00

CLDX vs IMNM, ELVN, VERA: FCF Margin % Comparison

For the Biotechnology subindustry, Celldex Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celldex Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's FCF Margin % falls into.

Save Embed

57GF Score

Celldex Therapeutics Inc CLDX

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Celldex Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Celldex Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-213.659	/	1.545
	=	-13,829.06 %

Celldex Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-67.227	/	0.015
	=	-448,180.00 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of -448,180.00% mean?

Celldex Therapeutics (CLDX) has a FCF Margin % of -448,180.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Celldex Therapeutics and its competitors. According to the industry distribution chart, Celldex Therapeutics ranks #923 out of 958 companies in the Biotechnology industry, placing it in the top 96.3%.

Is Celldex Therapeutics' FCF Margin % too high?

Celldex Therapeutics' current FCF Margin % is -448,180.00%. Based on the distribution chart, Celldex Therapeutics ranks #923 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Celldex Therapeutics' FCF Margin % compare to IMNM and ELVN?

According to the Biotechnology industry distribution chart, Celldex Therapeutics ranks #923 out of 958 companies for FCF Margin %. This places Celldex Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current FCF Margin % is -448,180.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Celldex Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.88, compared to a current price of $35.23 — trading 412.1% above its estimated fair value. The current FCF Margin % is -448,180.00%. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current FCF Margin % is -448,180.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $35.23 is trading 412.1% above its estimated GF Value™ of $6.88. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

FCF Margin %: -448,180.00%
GF Value™: $6.88 vs. price of $35.23 (412.1% above fair value)
GF Score™: 57/100 with 8 warning signs

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celldex Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies IMNM ELVN VERA TARS RARE IDYA MLYS KOD DFTX IRON VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges TCE2:Germany

Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827

Website https://www.celldex.com

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

57GF Score

Get the complete analysis for CLDX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.23

Price

$6.88

GF Value

View CLDX Analysis

See FCF Margin % data for all stocks →